Are you on the hunt for outsized returns for your ASX share portfolio?
If you are, it could be worth looking at the shares in this article that Morgans has been recommending to clients. Here's what the broker is saying:
Image source: Getty Images
GQG Partners Inc (ASX: GQG)
The first ASX share to look at is GQG Partners. Morgans has put an accumulate rating and $1.64 price target on this fund manager's shares this week.
Based on its current share price of $1.45, this implies potential upside of 13% for investors over the next 12 months. However, a dividend yield of around 10% is also expected, boosting the total potential return to 23%. It commented:
GQG has provided a May FUM update. Overall, monthly outflows appear to be stabilising in the -A$1.5bn to -A$2.0bn range, although investment performance remains highly volatile. While FUM is effectively flat calendar year-to-date, with outflows offset by positive market movements, we acknowledge it will be difficult for GQG to re-rate until the current outflow cycle ends. We lower our GQG FY26F/FY27F EPS forecasts by 1%-5% and reduce our price target to A$1.64 (from A$1.92). While the near-term operating environment remains difficult, we continue to see long-term value in the GQG franchise, trading at ~9x FY1 PE with a ~10% dividend yield. ACCUMULATE.
Helloworld Travel Ltd (ASX: HLO)
Another ASX share the broker has been looking at is Helloworld. Morgans has put a buy rating and $2.23 price target on this travel company's shares.
Based on its current share price of $1.39, this implies potential upside of around 60% for investors over the next 12 months. It said:
Given recent profit downgrades from other travel industry peers due to the conflict in the Middle East, HLO's downgrade wasn't a surprise. It has revised its FY26 EBITDA guidance by 11-14%. We have downgraded our forecasts. We assume that the conflict and a subdued consumer environment continue to impact the 1H27, followed by a strong recovery in the 2H27. This could prove conservative given HLO's strong 1Q27 bookings. We are buyers of HLO during this period of short-term uncertainty and share price weakness because when operating conditions ultimately improve, both its earnings and share price leverage to the upside will be material.
Tetratherix Ltd (ASX: TTX)
A higher risk option for investors is regenerative medicine company Tetratherix.
Morgans has a speculative buy rating and $7.15 price target on the company's shares. Based on its current share price of $5.31, this implies potential upside of approximately 35%. It commented:
TTX successfully completes a placement to fund the expansion of its production facility and build on its customer success team. We have updated our model to reflect the new capital and take a more optimistic stance on FDA approval for its dental/orthopedic products. Independent research shows TTX's drug delivery platform can safely carry and protect fragile drugs when delivered through the nose. Future licensing opportunities are likely. Our valuation has increased to A$7.15 (was A$6.84). SPECULATIVE BUY.
